OBJECTIVES: We examined the incidence of facial nerve stimulation in a population of patients with otosclerosis implanted with the Nucleus 22, Clarion 1.2, or Clarion High Focus (CHF) device. STUDY DESIGN AND SETTING: A retrospective chart review was used for 147 patients who had been implanted with electronic cochlear devices at the University of Minnesota between June 1986 and February 2001. Seventy-four patients were implanted with the Nucleus 22, 41 patients were implanted with the Clarion 1.2 (without a positioner), and 32 patients were implanted with the CHF I or II. RESULTS: Eleven (14.9%) of the 74 patients implanted with the Nucleus 22 device had facial stimulation. There were 9 patients with otosclerosis. Seven (78%) of the 9 patients with otosclerosis had facial stimulation. One (2.4%) of the 41 patients implanted with the Clarion 1.2 device (without a positioner) had facial stimulation and that 1 (100%) patient in the group had otosclerosis. There were 4 patients in the CHF group with otosclerosis. One patient experienced stimulation, but it was possible to decrease maximum current levels and still use the electrode pair. CONCLUSION: Facial stimulation appears to be less problematic in patients with otosclerosis implanted with the CHF devices.
OBJECTIVES: We examined the incidence of facial nerve stimulation in a population of patients with otosclerosis implanted with the Nucleus 22, Clarion 1.2, or Clarion High Focus (CHF) device. STUDY DESIGN AND SETTING: A retrospective chart review was used for 147 patients who had been implanted with electronic cochlear devices at the University of Minnesota between June 1986 and February 2001. Seventy-four patients were implanted with the Nucleus 22, 41 patients were implanted with the Clarion 1.2 (without a positioner), and 32 patients were implanted with the CHF I or II. RESULTS: Eleven (14.9%) of the 74 patients implanted with the Nucleus 22 device had facial stimulation. There were 9 patients with otosclerosis. Seven (78%) of the 9 patients with otosclerosis had facial stimulation. One (2.4%) of the 41 patients implanted with the Clarion 1.2 device (without a positioner) had facial stimulation and that 1 (100%) patient in the group had otosclerosis. There were 4 patients in the CHF group with otosclerosis. One patient experienced stimulation, but it was possible to decrease maximum current levels and still use the electrode pair. CONCLUSION: Facial stimulation appears to be less problematic in patients with otosclerosis implanted with the CHF devices.
Authors: Susan T Eitutis; Robert P Carlyon; Yu Chuen Tam; Marina Salorio-Corbetto; Zebunnisa Vanat; Karen Tebbutt; Rhian Bardsley; Harry R F Powell; Shibasis Chowdhury; James R Tysome; Manohar L Bance Journal: Otol Neurotol Date: 2022-04-01 Impact factor: 2.311
Authors: Iris Burck; Rania A Helal; Nagy N N Naguib; Nour-Eldin A Nour-Eldin; Jan-Erik Scholtz; Simon Martin; Martin Leinung; Silke Helbig; Timo Stöver; Annette Lehn; Thomas J Vogl Journal: Eur Radiol Date: 2021-07-05 Impact factor: 5.315